Streetbeat News

Products Services

BHC

Bausch Health (BHC) and Norwich Pharmaceuticals have filed for panel rehearing or rehearing en banc regarding their ongoing litigation. This move could delay the FDA's approval of Norwich's ANDA for up to 30 months or until a district court decision against Bausch Health.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:41 pm

GCTS

GCT Semiconductor announced progress in its 5G chipset development, expecting to offer broad sampling to customers in Q4 2024 and start volume shipments in H1 2025.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:39 pm

FLYW

Flywire Corporation (NASDAQ:FLYW), a global payments enablement and software company, announced the expansion of its third-party invoicing solution for students and institutions. This solution aims to streamline the payment process for sponsors covering tuition and fees, reducing administrative burdens and improving revenue for institutions by facilitating the creation, issuance, and tracking of invoices.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:34 pm

CVNA

Bloomberg reported that Carvana's CEO anticipates an improvement in used car sales due to an oversupply of new vehicles. This outlook suggests a potential positive shift in market dynamics for Carvana, possibly leading to increased revenue and market share.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:32 pm

PLSE

Pulse Biosciences, Inc. (NASDAQ:PLSE) announces leadership changes to support growth, appointing Burke T. Barrett as CEO and Kevin Danahy as Chief Commercial Officer. These changes come as the company prepares for the pilot launch of its FDA-cleared CellFX nsPFA Percutaneous Electrode System.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:31 pm

BLNK

Blink Charging has been selected as one of the official EV charging partners for the State of New York, marking a significant milestone for the company in expanding its footprint in the EV infrastructure sector.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:29 pm

PTGX

Protagonist Therapeutics announced additional data from the rusfertide Phase 2 REVIVE study will be presented at the EHA Congress in Madrid, Spain, June 13-16, 2024. The data includes a published abstract showing no QTc prolongation with rusfertide, based on a study in healthy subjects.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:28 pm

NBTX

NANOBIOTIX announced that the FDA has issued a 'Study May Proceed' letter for a randomized Phase 2 study evaluating NBTXR3 in Stage Three Lung Cancer. This marks a significant step forward in the development of NBTXR3, potentially impacting its future market position and investor sentiment towards NANOBIOTIX.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:27 pm

EOSE

Eos Energy Enterprises reaffirms its FY24 revenue outlook of $60M-$90M, with expectations of completing its first state-of-the-art manufacturing line's Site Acceptance Testing in Q2 2024. The company also forecasts a positive contribution margin in Q4 2024 due to cost reduction actions and production tax credits.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:27 pm

STTK

Shattuck Labs announced it will present additional data from the Phase 1B dose expansion trial of SL-172154 at the EHA 2024 Congress on June 14. This announcement could indicate significant progress in their research and development efforts, potentially impacting the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:25 pm